Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Trial Profile

Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rosiglitazone (Primary) ; Mesalazine
  • Indications Ulcerative colitis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2010 Primary endpoint 'Mayo score' has been met.
    • 19 Jan 2010 Status changed from active, no longer recruiting to completed according to results published in The American Journal of Gastroenterology.
    • 19 Jan 2010 Results have been published in The American Journal of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top